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Background: The association between heart failure (HF) and herpes zoster has rarely been studied. We investigated
the hypothesis that HF may increase the risk of herpes zoster in Taiwan using a nationwide Taiwanese population-
based claims database.
Method: Our study cohort consisted of patients who received a diagnosis of HF in 2001 ~ 2009 (N = 4785). For a
comparison cohort, three age- and gender-matched control patients for every patient in the study cohort were
selected using random sampling (N = 14,355). All subjects were tracked for 1 year from the date of cohort entry to
identify whether or not they had developed herpes zoster. Cox proportional-hazard regressions were performed to
evaluate 1-year herpes zoster-free survival rates.
Results: The main finding of this study was that patients with HF seemed to be at an increased risk of developing
herpes zoster. Of the total patients, 211 patients developed herpes zoster during the 1-year follow-up period,
among whom 83 were HF patients and 128 were in the comparison cohort. The adjusted hazard ratio (AHR) of
herpes zoster in patients with HF was higher (AHR: 2.07; 95% confidence interval (CI): 1.54 ~ 2.78; p < 0.001) than
that of the controls during the 1-year follow-up. Our study also investigated whether HF is a gender-dependent risk
factor for herpes zoster. We found that male patients with HF had an increased risk of developing herpes zoster
(AHR: 2.30 95% CI: 1.51 ~ 3.50; p < 0.001).
Conclusions: The findings of our population-based study suggest that patients with HF may have an increased risk
of herpes zoster. These health associations should be taken into consideration, and further studies should focused
on the cost-effectiveness of the herpes zoster vaccine should be designed for HF patients.
Keywords: Heart failure, Herpes zoster, Population-based study, Taiwan National Health Insurance Research
DatabaseBackground
Herpes zoster manifests as characteristic painful vesicu-
lar skin lesions and related neurological disorders usually
unilaterally grouped and limited to 1 to 3 dermatome.
Herpes zoster is caused by spontaneous reactivation of a
latent varicella-zoster virus (VZV) that resides in sensory
ganglia and dorsal nerve roots following a varicella infec-
tion [1]. Although most herpes zoster attacks resolve
spontaneously, several neurologic complications can* Correspondence: wpchang@mail.ypu.edu.tw
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unless otherwise stated.develop, including post-herpetic neuralgia, cranial nerve
palsies, myelitis, encephalitis, ventriculitis, and vasculop-
athy [2]. Post-herpetic neuralgia, the most common
complication, results in functional disability and a re-
duced quality of life. Herpes zoster also increases the
risk of stroke and cancer according to population-based
studies [3-6]. Therefore, herpes zoster has important im-
pacts on the health of adults, particularly the elderly,
and on health systems.
The estimated lifetime risk of herpes zoster is 10% ~
30%, and the incidence and severity markedly increase
after the age of 50 years [7-11]. The incidence of herpes
zoster in the general population is 1.2 ~ 4.9 cases peris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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incidence is 0.42 per 1000 person-years [1]. Old age is the
most well-known risk factor for herpes reactivation [14].
Other established risk factors for herpes zoster include
diabetes mellitus, chronic obstructive pulmonary disease
(COPD), malignancy, and immune-compromised condi-
tions (eg., patients with AIDS, systemic lupus nephritis,
and rheumatoid arthritis, and transplant recipients,)
[15-25]. Although the mechanism of reactivation of latent
VZV remains unclear, decreasing cellular immunity to
VZV predisposes one to the recurrence of herpes zoster
[26,27].
Heart failure (HF) has high prevalence rate among eld-
erly patients and increases with aging [28,29]. Dissemi-
nated zoster in elderly patients with hypertension and
HF was previously reported [30]. Furthermore, higher
herpes zoster risk among patients with cardiovascular
disease was also found [31]. There are no published data
regarding the exact herpes zoster incidence occurring in
a large sample of patients with HF. The purpose of our
study was to investigate whether patients with HF have a
higher incidence of herpes zoster than general popula-
tion. This study provides unique data based on the Lon-
gitudinal Health Insurance Database (LHID).
Methods
Data source
National Health Insurance (NHI) is a mandatory health
insurance program in Taiwan that provides comprehen-
sive coverage for medical care. Up to 99% of the popula-
tion was enrolled by 2009. All claims data are collected
in the NHI Research Database (NHIRD) and are man-
aged by the Taiwan National Health Research Institutes
(NHRI).
The NHIRD consists of comprehensive healthcare data
provided to researchers, including ambulatory care re-
cords, inpatient care records, registration files, cata-
strophic illness files, and various data regarding drug
prescriptions of the insured among 23.5 million Taiwanese
residents. Data used to perform the analyses conducted in
this study were retrieved from the LHID 2005, a subset of
the NHIRD. The LHID2005 consists of all the original
medical claims for 1,000,000 enrollees' historical ambula-
tory data and inpatient care data under the Taiwan NHI
program from 1997 to 2010, and the database was created
and is publicly released to researchers.
The NHRI, which constructed and maintains the
LHID2005 database, further scrambles this encrypted in-
formation before the database is released to researchers.
The NHRI reported that there were no statistically signifi-
cant differences in age or gender between the randomly
sampled group and all beneficiaries of the NHI program.
To maintain claims data accuracy, the NHI’s routine prac-
tice of performing cross-checks and validations of medicalclaims ensures the accuracy of the NHIRD diagnostic
coding.
Study population
We used a study cohort and a comparison cohort to
examine the relationship between HF and herpes zoster.
We identified 4785 first-time hospitalizations with a dis-
charge diagnosis of HF (International Classification of
Disease, 9th Revision, Clinical Modification (ICD-9-CM)
codes 398.91, 402.01, 402.11, 402.91, 404.01, 404.03,
404.11, 404.13, 404.91, 404.93, or 428) between January
2001 and December 2009. The date of the initial diagno-
sis of HF was assigned as the index date for each HF pa-
tient. To improve data accuracy, the HF selection
criterion required that all case ICD-9 codes by assigned
by a cardiologist. We also chose selection criteria for
herpes zoster patients. We only included herpes zoster
cases in this study if they received ≥ 2 herpes zoster diag-
noses for ambulatory care visit or ≥ 1 diagnosis for in-
patient care.
Our study used a study cohort and a comparison co-
hort to examine the relationship between HF and herpes
zoster. Each HF cohort patient was matched based on
age, gender, and index year to three randomly identified
beneficiaries without HF to build the comparison cohort.
Patients diagnosed with herpes zoster (ICD-9-CM code
053–053.9) before or after the study period were ex-
cluded from both cohorts. We also identified relevant
comorbidities, including hypertension (ICD-9-CM 401.
X-405.X), diabetes mellitus (ICD-9-CM 250.X), hyperlip-
idemia (ICD-9-CM 272.X), systemic lupus erythematous
(ICD-9-CM 710.0), COPD (ICD-9-CM 491.X), rheuma-
toid arthritis (ICD-9-CM 714.0), and cancer (ICD-9-CM
140.X-208.X).
Level of urbanization
For our study of urbanization, all 365 townships in
Taiwan were stratified into 7 levels according to the
standards established by the Taiwanese NHRI based on a
cluster analysis of the 2000 Taiwan census data, with 1
referring to the most urbanized area and 7 referring to
the least urbanized. The criteria on which these strata
were determined included the population density (per-
sons/km2), the number of physicians per 100,000 people,
the percentage of people with a college education, the
percentage of people over 65 years of age, and the per-
centage of agricultural workers. Because levels 4, 5, 6,
and 7 contained few HF cases, they were combined into
a single group, thereafter referred to as level 4.
Statistical analysis
All data processing and statistical analyses were per-
formed with the Statistical Package for Social Science
(SPSS) software, vers. 18.0 (SPSS, Chicago, IL, USA) and
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Cary, NC, USA). Pearson X 2 tests were used to compare
differences in geographic location, monthly income, and
urbanization level of patients’ residences between the
study and comparison groups. We also performed a sur-
vival analysis using the Kaplan-Meier method, and used
the log-rank test to compare survival distributions be-
tween cohorts. The survival period was calculated for
patients who suffered from HF until an occurrence of
hospitalization, an ambulatory visit for herpes zoster, or
the end of the study period (December 31, 2010), which-
ever came first. After adjusting for urbanization level,
monthly income, region, and comorbidities as potential
confounders, we performed a Cox proportional-hazards
analysis stratified by gender, age group, and index year
to examine the risk of herpes zoster during the 1-year
follow-up in both cohorts. We further classified the gen-
der and age factors in both groups. Hazard ratios (HRs)
and 95% confidence intervals (CIs) were calculated to
quantify the risk of herpes zoster. The results of compar-
isons with a two-sided p value of < 0.05 were considered
to represent statistically significant differences.Ethical approval
Insurance reimbursement claims adopted in this study
were from Taiwan’s NHIRD, which is available for research
purposes. This study was conducted in accordance with
the Helsinki Declaration. This study was also evaluated
and approved by the Kaohsiung Medical University Hos-
pital Institutional Review Board (KMUH-IRB-EXEMPT-
20130059).Figure 1 Flow chart of selection of study subjects and control subjec
in Taiwan.Results
The research design of this study is shown in Figure 1.
The HF cohort contained 4785 patients, and 14,355 pa-
tients were included in the comparison cohort. Distribu-
tions of demographic characteristics and comorbidities for
the HF and comparison cohorts are shown in Table 1.
Hypertension (p < 0.001), hyperlipidemia (p < 0.001), dia-
betes (p < 0.001), and COPD (p < 0.001) were more preva-
lent in the HF cohort than the comparison cohort. We
also found that cases had a greater tendency to have a
lower monthly income (p < 0.001), and to reside in south-
ern and eastern Taiwan, and reside in less-urbanized com-
munities (p < 0.001) compared to controls.
There were 211 patients diagnosed with herpes zoster
during the 1-year follow-up, including 83 HF patients (1.7%)
and 128 patients in the comparison cohort (0.9%). The
Kaplan-Meier survival curves are shown in Figure 2. The
curves demonstrate significantly lower herpes zoster-free
survival rates in the HF cohort than in the comparison co-
hort (log-rank test, p < .001). The overall incidence rate was
higher in the HF cohort (17.61 per 1000 patient-years) than
in the comparison cohort (8.95 per 1000 patient-years).
The Cox regression analysis showed that the crude HR
for herpes zoster was 1.96-times greater for HF patients
(95% CI: 1.49 ~ 2.59; p < 0.001) than for comparison pa-
tients. After adjusting for potential confounders, our re-
sults showed that newly diagnosed HF was associated
with an approximately 2.07-times greater risk of herpes
zoster (95% CI: 1.54 ~ 2.78; p < 0.001), compared to non-
HF patients (Table 2).
We further investigated whether HF is a time-
dependent risk factor for herpes zoster and divided HFts from the National Health Insurance Research Database
Table 1 Demographic characteristics for the selected patients, stratified by presence/absence of heart failure from
2001 to 2009 (n = 19140)
Patients with heart failure (n = 4785) Patients without heart failure (n = 14355) P value
n % N %
Gender 1
Male 2547 53.2 7641 53.2
Female 2238 46.8 6714 46.8
Age (Years) 1
18-40 197 4.1 591 4.1
41-65 1359 28.4 4077 28.4
66-80 2132 44.6 6396 44.5
81- 1097 22.9 3291 22.9
Follow-up, year, mean (SD) <0.001
0.94 0.12 0.996 0.06
Urbanization level <0.001
1 (most urbanized) 1230 25.7 4396 30.6
2 1256 26.2 3532 24.6
3 710 14.8 2164 15.1
4 (least urbanized) 1589 33.2 4263 29.7
Monthly income <0.001
0 1572 32.9 4515 31.5
NT$ 1-15840 1229 25.7 2911 20.3
NT$ 15841-25000 1695 35.4 5377 37.5
≧25001 289 6.0 1552 10.8
Geographic region <0.001
North 1996 41.7 6392 44.5
Central 1224 25.6 3612 25.2
South 1191 24.9 3561 24.8
Eastern 374 7.8 790 5.5
Hypertension <0.001
Yes 4333 90.6 9606 66.9
No 452 9.4 4749 33.1
Hyperlipidemia <0.001
Yes 2472 51.7 6007 41.8
No 2313 48.3 8348 58.2
Diabetes <0.001
Yes 2720 56.8 4952 34.5
No 2065 43.2 9403 65.5
SLE 0.94
Yes 17 0.4 52 0.4
No 4768 99.6 14303 99.6
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Table 1 Demographic characteristics for the selected patients, stratified by presence/absence of heart failure from
2001 to 2009 (n = 19140) (Continued)
Rheumatoid arthritis 0.51
Yes 303 6.3 871 6.1
No 4482 93.7 13484 93.9
COPD <0.001
Yes 3265 68.2 6928 48.3
No 1520 31.8 7427 51.7
Cancers 0.53
Yes 923 19.3 2710 18.9
No 3862 80.7 11645 81.1
SD: Standard deviation.
COPD: Chronic obstructive pulmonary disease.
SLE: Systemic Lupus Erythematous.
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For the three different follow-up periods, there was still
statistical significance between the case and comparison
groups. The 1-month follow-up period had the highest
statistical significance (AHRs: 4.52; 95% CI: 2.28 ~ 8.96;
p < 0.001) (Table 3). We also further conducted gender-
and age-stratified analyses, and results revealed that
male subjects (HR: 2.30; 95% CI: 1.51 ~ 3.50; p < 0.001)
had a higher risk of developing herpes zoster than fe-
male subjects (HR: 1.92; 95% CI: 1.27 ~ 2.92; p < 0.01).
For 41 ~ 65 year olds, there was the highest risk (HR:Figure 2 Herpes Zoster-free survival rates for patient with heart failu3.14; 95% CI: 1.56 ~ 6.21; p < 0.01) for developing herpes
zoster (Table 4).
Discussion
This cohort study demonstrated that, after controlling
for other herpes zoster risk factors, patients with HF
were at a 2.07 times increased risk than the general
population to experience herpes zoster during the 1-year
follow-up period. After further stratification by age, gen-
der, and follow-up period, we found a consistent in-
creased herpes zoster risk in HF patients compared tore patients and comparison groups from 2001 to 2009.
Table 2 Hazard ratios (HRs) of Herpes Zoster among heart failure patients during the 1-year follow-up period from the
index ambulatory visits or inpatient care from 2001 to 2009
Total Patients with heart failure Patients without heart failure
Development of Herpes Zoster NO. (%) NO. (%) NO. (%)
1-year follow-up period
Yes 211 1.1 83 1.7 128 0.9
No 18929 98.9 4702 98.3 14227 99.1
Crude HR (95% CI) 1.96 (1.49-2.59)* 1
Adjusted HR (95% CI) 2.07 (1.54-2.78)* 1
Total sample number =19140.
Both crude and adjusted HRs were calculated by Cox proportional hazard regressions.
Adjustments are made for patients’ Sex, Age, Urbanization level, Geographic region, Monthly income, Hypertension, Hyperlipidemia, Diabetes, and Chronic
obstructive pulmonary disease.
*Indicates p < 0.001.
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first cohort study to investigate the risk of herpes zoster
in patients with HF.
Patients with suppressed cell-mediated immunity cause
by immunosuppressive disorders or therapies, such as eld-
erly people, patients with autoimmune disease, malignancy,
or diabetes, are well described as having a higher risk of de-
veloping herpes zoster [14,15,19-24]. Psychosocial stress
also appears to reduce immunological control over a latent
herpes virus [32], particularly VZV [33]. Patients with ad-
vanced HF are associated with many physiological and psy-
chological stressors [34,35], which may increase the risk of
herpes zoster. This could partially explain the association
between HF patients was increased risk of HZ, especially
occurred shortly after the incident HF hospitalization. Be-
sides, natural killer cell dysfunction, which was found in
patients with HF [36], was related to reactivation of the HZ
in some studies [37]. However, mechanisms that explain
the increased risk of herpes zoster in patients with HF re-
main unclear.
The major morbidity caused by herpes zoster is post-
herpetic neuralgia, which consumes a lot of medical re-
sources [38]. The pain of herpes zoster can last for
months or years, and treating the complication often re-
quires a multifaceted approach. Besides, several studiesTable 3 Hazard ratios (HRs) of Herpes Zoster among heart fai
follow-up period from the index ambulatory visits or inpatien
1-month follow-up period
Development of Herpes Zoster Patients with
heart failure
Comparison
Yes (%) 21 (0.4) 18 (0.1)
No (%) 4764 (99.6) 14337 (99.9)
Crude HR (95% CI) 3.51 (1.87-6.59)* 1
Adjusted HR (95% CI) 4.52 (2.28-8.96)* 1
Total sample number =19140.
Both crude and adjusted HRs were calculated by Cox proportional hazard regressio
Adjustments are made for patients’ Sex, Age, Urbanization level, Geographic region
*Indicates p < 0.001.document an association between diagnosis of herpes
zoster and subsequent diagnosis of cancer [5,6,39,40].
Herpes zoster could be an early manifestation of the
immune-system impairment associated with malignancy.
It is hypothesis that reactivation of VZV triggers some
immunologic mechanisms, such as tissue antigen alter-
ation or antigenic stimulation, which could result in can-
cer [41]. Determining the risk of cancer following zoster
is important because it raises the potential for case find-
ing to facilitate earlier cancer diagnosis. Nowadays, zos-
ter vaccines were documented to markedly reduce the
morbidity related to herpes zoster in the immune-
competent elderly [42]. As the zoster vaccine was avail-
able in Taiwan, the present study provides background
data of herpes zoster risk in HF patients, and further
studies should focus on the cost-effectiveness of the her-
pes zoster vaccine in this special population. In addition,
we propose a need for further research on the varicella
vaccine possibly decreasing relapses of herpes zoster,
and associated complications and medical costs in HF
patients.
The present study has a number of strengths. First,
this is a large-scale follow-up study using the well-
established nationwide NHI research database. The
study cohort was highly representative of the generallure patients during the 1-month, 6-month and 1-year
t care from 2001 to 2009






50 (1.0) 62 (0.4) 83 (1.7) 128 (0.9)
4735 (99.0) 14293 (99.6) 4702 (98.3) 14227 (99.1)
2.44 (1.68-3.54)* 1 1.96 (1.49-2.59)*** 1
2.67 (1.79-3.98)* 1 2.07 (1.54-2.78)*** 1
ns, and stratified by age and sex.
, Monthly income, Hypertension, Hyperlipidemia, Diabetes, and COPD.
Table 4 Overall and age- and sex-specific incidence rate and relative hazard of Herpes Zoster in the heart failure and
comparison cohorts





Incident cases Person-year IR1 per 1000
patient-years
Agea
18-40 1 196.24 5.10 (−4.87-15.06) 1 590.34 1.69 (−1.62-5.01) 3.00 (0.19-47.92) 7.81 (0.28-215.54)
41-65 23 1341.56 17.14 (10.20-24.09) 22 4066.38 5.41 (3.16-7.66) 3.16 (1.76-5.68)*** 3.14 (1.59-6.21)**
66-80 37 2092.79 17.68 (12.03-23.33) 72 6361.81 11.32 (8.72-13.92) 1.56 (1.05-2.32)* 1.66 (1.09-2.53)*
81- 22 1081.41 20.34 (11.93-28.76) 33 3278.74 10.06 (6.65-13.48) 2.02 (1.18-3.46)* 2.26 (1.29-3.96)**
Sexb
Male 42 2514.55 16.70 (11.69-21.71) 61 7612.37 8.01 (6.01-10.02) 2.08 (1.41-3.08)*** 2.30 (1.51-3.50)***
Female 41 2197.45 18.66 (13.00-24.32) 67 6684.89 10.02 (7.63-12.41) 1.86 (1.26-2.74)** 1.92 (1.27-2.92)**
Total 83 4712.00 17.61 (13.86-21.37) 128 14297.27 8.95 (7.41-10.50) 1.96 (1.49-2.59)*** 2.07 (1.54-2.78)***
IR indicates incidence rate.
1Based on the Poisson assumption.
aAdjusted for patients’ Sex, Age, Urbanization level, Geographic region, Monthly income, Hypertension, Hyperlipidemia, Diabetes, COPD.
bAdjusted for patients’ Age, Urbanization level, Geographic region, Monthly income, Hypertension, Hyperlipidemia, Diabetes, and COPD.
*Indicates p < 0.05; ** Indicates p < 0.01; *** Indicates p < 0.001.
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and accurate because the NHI is a compulsory and uni-
versal healthcare system with a very high coverage rate
in Taiwan. In addition, while racial differences are con-
sidered to be a factor that influences the risk of herpes
zoster [14], approximately 98% of Taiwan’s residents are
of Han Chinese ethnicity; this relatively homogenous
population reduces potential confounding by race in our
study. Furthermore, with the NHIRD, claims for each in-
sured can be tracked across time. In the present study,
all claims of different medical institutes during the study
period were obtained for analysis. This avoided the bias
of patients dropping out that occurs in most longitudinal
studies and minimized the possibility of recall bias.
Nevertheless, some insufficiencies should be addressed.
First, almost all herpes zoster and HF cases were diag-
nosed clinically without serologic confirmation or stan-
dardized procedure, so diagnoses based on ICD-9-CM
codes may be less accurate. However, the NHI Bureau in
Taiwan randomly interviews patients and reviews medical
records every year to confirm the validity of the diagnoses
and quality of care. In addition, the validity of the coding
for herpes zoster and HF in administrative data was shown
to be good [22,43]. Second, some patients with herpes zos-
ter might have been missed in our database if they did not
seek medical help, particularly if their symptoms were
mild. Miscoding and misclassification could occur as po-
tential biases. However, utilization of medical services in
Taiwan is generally high because there are very low finan-
cial barriers to medical care in a very low copayments sys-
tem. Patients are responsible for a copayment of only US
$3 ~ 15 each visit, so most patients with herpes zoster
would seek medical attention after disease onset. Thus,
the number of herpes zoster cases not included in NHIRDis likely to be small [3]. Third, the claims database lacks
information on cigarette smoking, alcohol consumption,
dietary habits, physical activities, environmental exposure,
nutritional status, and family history, which may confound
our findings. In addition, an information bias may arise if
the HF patients have a greater tendency to visit physicians
than the non-HF patients. Another information bias may
occur if physicians are more alert to the diagnosis of her-
pes zoster in patients with HF than in patients without
HF. The administrative database cannot offer information
about the HF disease severity, which may also be a con-
founding factor for the results of the present study.
Fourth, the dataset was not directly linked to the national
death registry. Therefore, we could not evaluate the mor-
tality between HF and comparison groups during follow-
up period. Finally, most residents of Taiwan are of Chinese
ethnicity. The ability to generalize our results to other eth-
nic/racial groups is unclear, and they should be interpreted
with caution.
Conclusions
In conclusion, the present study suggests a positive associ-
ation between HF and herpes zoster. Physicians, including
dermatologists and cardiologists, should be aware of the
greater incidence of herpes zoster among patients with
HF. They should also be familiar with proper antiviral
therapy, as well as acute and chronic pain management.
Immune-compromised patients should receive the herpes
zoster vaccine for preventive purposes. Future studies are
needed to investigate the possible mechanism between dif-
ferent stages of HF and herpes zoster.
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